Today’s AI Top Pick: SPRO

7/23/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW9.1 / 107/23/2026

SPRO is the standout contrarian bounce here — it combines the strongest fundamentals in the entire pool (fundamental_score 8, PE 5.21, fwdPe 1.9, ROE 35.12%, profit margin 27.82%, debtEq 0.05) with a monster recent positive catalyst that most of the market seems to have missed. On July 15 Innovent licensed IBI355 to Spero for up to $1.1B, and analysts flagged it as a 'Buy' on the Utebzi royalty deal. This is a real fundamental repricing event landing into a name that is still bombed out (drawdown -40%, YTD -45.5%, RSI 20.69 — deeply oversold). The multi-timeframe picture is exactly what a contrarian bounce setup should look like: 1h fc_short +99.88%, 4h +97.79%, 1d +51.13% short / +78.41% mid, and even the 1wk (+53%/+23%/+11%) all point up. near_term_bullish is 1.0, kronos bullish_prob is 1.0. Critically, position_in_21bar_range is only 7.4% on the 1d and 7.6% on the 4h — this is a base, not a chase. The 1h has already reclaimed 59.5% of range, which suggests the actual bottom is in and buyers are stepping in, but the higher timeframes haven't fully re-rated yet — that's the window. Compare that to the alternatives. IBM literally had its worst day in decades today with a lowered annual outlook — the forecast is stale relative to the news. LESL is reportedly considering Chapter 11. TVRD is doing an ATM raise. LUCY just exercised warrants (dilution). HCWB just did a 1-for-6 reverse split. IONQ has analyst-flagged profitability concerns. SPRO by contrast has a fresh, big, unambiguously positive catalyst with real cash implications, plus a Maxim/Wainwright-style Buy setup — and it's still trading like nothing happened. TODAY is the entry because you have (a) exhausted seller conditions (RSI 20 with -40% drawdown), (b) forecasts turning up across every timeframe, (c) a legitimate fundamental catalyst that hasn't been priced in yet, and (d) analyst target upside of 215%. Waiting for a lower low means missing the mean-reversion move that the models are calling with probability 1.0.

Entry zone

$1.28 - $1.38 (add on any dip toward $1.25; current $1.34)

Stop loss

$1.10 (below the 21-bar low; ~18% risk)

First target

$2.00 (near 1d fc_short +51% and 4h fc_mid +82%)

Longer target

$2.40 - $2.65 (fc_short/mid alignment ~+90%, still well below analyst target upside of 215%)

Risks

Micro-cap ($73.5M market cap) — thin liquidity means gap risk in either direction
1wk fc_long is only +11.36% — the long-run signal is weakest, so this is a swing trade not a hold-forever
Deal-cash burn: biotech licensing deals can take time to translate to real revenue; if Innovent milestones slip, the fundamental case weakens
Analyst recom is 3.0 (Hold, not Buy) despite the target upside — Wall Street is still skeptical
Short float 6.69% is modest but any negative FDA/clinical news on SP001 in-licensing could kill the bounce

Honorable mentions

CRVOStrong multi-TF forecast alignment (1d +104% short / +120% mid, 1wk +77%/+155%), near_term_bullish 1.0, HC Wainwright Buy reiterated with $25 target, fresh positive AAIC clinical data on neflamapimod — but fundamentals are weaker than SPRO (roe -132, op margin -1488%).

TEMMulti-TF all positive (1d +10.7/+41.5/+31%), near_term 1.0, and a huge news catalyst with the $1.5B Personalis deal cornering the cancer-test market — held back by stretched valuation (ps 6.18, debtEq 3.17) and 31.67% short float.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	9.1	Best fundamentals in pool + $1.1B Innovent deal + all-TF bullish + RSI 20 oversold — textbook contrarian bounce.
2	CRVO	BUY NOW	7.8	All TFs green with huge 1d/1wk forecasts and fresh positive AAIC clinical data plus $25 Wainwright target.
3	TEM	BUY NOW	7.5	Multi-TF alignment plus $1.5B Personalis acquisition to dominate cancer testing — near_term 1.0.
4	SST	BUY NOW	7.2	All-TF forecasts stacked strongly bullish (1d +73/+119/+164%) with 1h already reclaiming 78% of range.
5	BESS	BUY PULLBACK	7.0	Solid fundamental_score 6, strong FPUSA project news, but near_term only 0.4 — wait for 4h base.
6	ANY	BUY PULLBACK	6.8	Massive 1d forecasts (+161/+195/+170%) and DarkHorse rebrand catalyst; near_term 1.0 but thin float.
7	GRRR	BUY PULLBACK	6.6	$232M bond raise accelerates AI infrastructure execution; 1wk fc +49/+66/+79% supports the setup.
8	AKTX	BUY PULLBACK	6.4	Maxim Buy $30 target and Whitehawk collab; 1d fc +40/+119/+66% but 1h forecasts negative — needs consolidation.
9	HCWB	BUY PULLBACK	6.2	Massive 1wk fc +641% and near_term 1.0 but recent 1-for-6 reverse split is a red flag for retail momentum.
10	ASPI	BUY PULLBACK	6.0	Helium/Noble Africa listing catalyst plus 511% sales YoY, but 1wk fc turns negative — swing only.
11	TGEN	BUY PULLBACK	5.9	$3.3M PO / $8M backlog and near_term 0.8, but 1wk fc negative (-5/-34/-48%) undercuts the swing case.
12	CRML	WAIT	5.7	Rare-earth story real but Simply Wall St. calling it overvalued after asset review — heavy 31.5% short float.
13	CALC	WAIT	5.5	FDA cleared Auxora trial continuation but the $49M placement is dilutive overhang; 1d fc +234% is aggressive.
14	IONQ	WAIT	5.4	Multi-TF near_term 0.8 but profitability concerns flagged and 1wk fc negative; wait for better setup.
15	INV	WAIT	5.2	1h/4h/1d/1wk all up but ps 86.62 and profit margin -5226% are absurd; CEO transition Oct 1 adds uncertainty.
16	PEW	WAIT	5.0	Suppressor DTC expansion is thematic but 1d fc only +16/+36/+39% — modest for a bounce play.
17	SKIN	WAIT	4.9	Zacks Strong Buy upgrade and FDA clearance help but 1h fc turns negative and 1wk fc_short is -30%.
18	BIRD	WAIT	4.7	Post-rebrand momentum from Allbirds → Smartbird pivot, but fundamental_score -3 and 4h/1wk mixed.
19	PMEC	WAIT	4.6	$2.67M contract wins are nice but tiny ($19M market cap) and near_term 1.0 but institutional own 0.08%.
20	ONMD	WAIT	4.4	1wk fc +94/+232/+293% is huge but resale prospectus for 11.68M shares is a dilution overhang.
21	LUCY	WAIT	4.2	Claude AI integration is intriguing but $3M warrant exercise is dilutive and 1h fc only +22%.
22	TVRD	WAIT	4.0	149% weekly rally already occurred and ATM offering increased to $9.69M — dilution risk into strength.
23	DSY	WAIT	3.9	1wk fc +273/+473/+654% is eye-popping but roe -9117% and profit margin -1800% is a red flag.
24	SG	WAIT	3.7	Citi buy at $10 but near_term only 0.4 and 1wk fc_short only +1.5% — momentum not yet turning.
25	TROLL-USD	AVOID	3.5	1d forecast is -98% across all horizons — signal is broken despite kronos_prob 1.0.
26	NN	AVOID	3.3	1wk fc all negative and analyst fair value cut on spectrum uncertainty — momentum broken.
27	GTBP	AVOID	3.2	near_term_bullish 0 and 1d forecasts negative (-9/-12%); setup contradicts the bullish_prob.
28	RXRX	AVOID	3.0	Fundamental_score -3.5, roe -57, 36.6% short float — falling more than broader market repeatedly.
29	IBM	AVOID	2.8	Worst day in decades TODAY on lowered annual revenue outlook — forecast is stale to the news.
30	LESL	AVOID	1.5	Bloomberg reporting potential Chapter 11 consideration — do not touch regardless of forecast.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord